Condition: Anaplastic Large Cell Lymphoma, ALK-Positive · Inflammatory Myofibroblastic Tumor · Other Solid Tumor · Sponsor: Princess Maxima Center for Pediatric Oncology
This is an open-label, phase I-II dose-escalation and expansion study designed to define the recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors and to evaluate the pharmacokinetics (PK), (long-term) safety, and efficacy of brigatinib in these children.
This description comes directly from the study's public registry record.
Maaike Boonstra · +31642055985 · m.boonstra@prinsesmaximacentrum.nl
Gertruud Bakker · +31889727272 · G.C.M.Bakker-7@prinsesmaximacentrum.nl
Always discuss trial participation with your own doctor first.
| Institut Gustave Roussy | Paris, France | Recruiting |
| Princess Máxima Center for Pediatric Oncology | Utrecht, Utrecht, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04925609